Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Statistics
  • Help & Advice
University of Warwick

The Library

  • Login

Validation and reliability of the neuropathic pain scale (NPS) in multiple sclerosis

Tools
- Tools
+ Tools

Rog, David J., Nurmikko, Turo J., Friede, Tim and Young, Carolyn A.. (2007) Validation and reliability of the neuropathic pain scale (NPS) in multiple sclerosis. Clinical Journal of Pain, Vol.23 (No.6). pp. 473-481. ISSN 0749-8047

Full text not available from this repository.
Official URL: http://dx.doi.org/10.1097/AJP.0b013e31805d0c5d

Abstract

Objective: Central neuropathic pain Occurs in around 28% of patients with multiple sclerosis (MS). The Neuropathic Pain Scale (NPS) has received preliminary validation in peripheral neuropathic pain conditions. The aim of this study was to validate its use in MS central pain syndromes. Methods: We administered the NPS to 141 patients with MS, together with the Short Form McGill Pain Questionnaire (SFMPQ), the Hospital Anxiety and Depression Scale (HADS), and Short Form 36 Health Survey (SF-36). Results: Cronbach's alpha was 0.78 (95% CI 0.69; 0.83), implying a high degree of internal consistency. Three factors, "Familiar," "Superficial," and "Alien Perception," were extracted, accounting for 64% of the variance. The NPS 10-item total correlates with: the SFMPQ 15-item total score, rho = 0.63 (95% CI 0.49; 0.74), its Visual Analog Scale, rho = 0.49 (95% CI 0.33; 0.64), the transformed Pain domain of the SF-36 rho = 0.49 (95% Cl - 0.63; - 0.32), but not with its remaining seven health domains, or with either the HADS anxiety or the depression scores. Limits of agreement for short-term test or re-test reliability of the 100 point NPS total (median 2 days, range 1 to 7) were - 12 to 14 and when administered to 78 patients who rated their neuropathic pain the "Same" [median interval 33 days (range 19 to 126), the long-term test or re-test correlation coefficient was 0.71 (95% CI 0.6; 0.79)]. Discussion: The NPS appears a useful tool in the assessment of neuropathic pain in MS patients and possibly in measuring outcomes of therapeutic interventions.

Item Type: Journal Article
Subjects: R Medicine > RD Surgery
R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
Divisions: Faculty of Medicine > Warwick Medical School
Journal or Publication Title: Clinical Journal of Pain
Publisher: Lippincott Williams & Wilkins
ISSN: 0749-8047
Date: July 2007
Volume: Vol.23
Number: No.6
Number of Pages: 9
Page Range: pp. 473-481
Identification Number: 10.1097/AJP.0b013e31805d0c5d
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
URI: http://wrap.warwick.ac.uk/id/eprint/31747

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item View Item
twitter

Email us: publications@warwick.ac.uk
Contact Details
About Us